Spyre Therapeutics launches Phase 1 trials for its extended half-life IBD therapy
By Larissa Warneck-Silvestrin
Spyre Therapeutics launches Phase 1 trials for its extended...
Roche acquires CAR-T developer Poseida Therapeutics for $1.5 billion
Amgen announces positive Phase 2 results for its GLP-1-GIP weight...
BridgeBio wins FDA approval for inherited cardiomyopathy treatment
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular...
We’ve upgraded BioPharmaReporter to give you more of what you love
→
→
→
→